Literature DB >> 18713977

Antigen persistence is required for dendritic cell licensing and CD8+ T cell cross-priming.

Hélène Jusforgues-Saklani1, Martin Uhl, Nathalie Blachère, Fabrice Lemaître, Olivier Lantz, Philippe Bousso, Deborah Braun, James J Moon, Matthew L Albert.   

Abstract

It has been demonstrated that CD4(+) T cells require Ag persistence to achieve effective priming, whereas CD8(+) T cells are on "autopilot" after only a brief exposure. This finding presents a disturbing conundrum as it does not account for situations in which CD8(+) T cells require CD4(+) T cell help. We used a physiologic in vivo model to study the requirement of Ag persistence for the cross-priming of minor histocompatibility Ag-specific CD8(+) T cells. We report inefficient cross-priming in situations in which male cells are rapidly cleared. Strikingly, the failure to achieve robust CD8(+) T cell activation is not due to a problem with cross-presentation. In fact, by providing "extra help" in the form of dendritic cells (DCs) loaded with MHC class II peptide, it was possible to achieve robust activation of CD8(+) T cells. Our data suggest that the "licensing" of cross-presenting DCs does not occur during their initial encounter with CD4(+) T cells, thus accounting for the requirement for Ag persistence and suggesting that DCs make multiple interactions with CD8(+) T cells during the priming phase. These findings imply that long-lived Ag is critical for efficient vaccination protocols in which the CD8(+) T cell response is helper-dependent.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18713977     DOI: 10.4049/jimmunol.181.5.3067

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses.

Authors:  Philippe Krebs; Michael J Barnes; Kristin Lampe; Karen Whitley; Keith S Bahjat; Bruce Beutler; Edith Janssen; Kasper Hoebe
Journal:  Blood       Date:  2009-04-30       Impact factor: 22.113

2.  CD8+ T Cells Orchestrate pDC-XCR1+ Dendritic Cell Spatial and Functional Cooperativity to Optimize Priming.

Authors:  Anna Brewitz; Sarah Eickhoff; Sabrina Dähling; Thomas Quast; Sammy Bedoui; Richard A Kroczek; Christian Kurts; Natalio Garbi; Winfried Barchet; Matteo Iannacone; Frederick Klauschen; Waldemar Kolanus; Tsuneyasu Kaisho; Marco Colonna; Ronald N Germain; Wolfgang Kastenmüller
Journal:  Immunity       Date:  2017-02-09       Impact factor: 31.745

Review 3.  Dying cells actively regulate adaptive immune responses.

Authors:  Nader Yatim; Sean Cullen; Matthew L Albert
Journal:  Nat Rev Immunol       Date:  2017-03-13       Impact factor: 53.106

Review 4.  T cell responses to antigen: hasty proposals resolved through long engagements.

Authors:  Karen Tkach; Grégoire Altan-Bonnet
Journal:  Curr Opin Immunol       Date:  2012-12-28       Impact factor: 7.486

5.  Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?

Authors:  Pawel Kalinski; Howard Edington; Herbert J Zeh; Hideho Okada; Lisa H Butterfield; John M Kirkwood; David L Bartlett
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

6.  Serine protease inhibitor 6 is required to protect dendritic cells from the kiss of death.

Authors:  Elena Lovo; Manling Zhang; Lihui Wang; Philip G Ashton-Rickardt
Journal:  J Immunol       Date:  2012-01-06       Impact factor: 5.422

Review 7.  Cross-presentation of IgG-containing immune complexes.

Authors:  Kristi Baker; Timo Rath; Wayne I Lencer; Edda Fiebiger; Richard S Blumberg
Journal:  Cell Mol Life Sci       Date:  2012-07-31       Impact factor: 9.261

8.  Exploring the immunopotentiation of Chinese yam polysaccharide poly(lactic-co-glycolic acid) nanoparticles in an ovalbumin vaccine formulation in vivo.

Authors:  Li Luo; Tao Qin; Yifan Huang; Sisi Zheng; Ruonan Bo; Zhenguang Liu; Jie Xing; Yuanliang Hu; Jiaguo Liu; Deyun Wang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 9.  In vivo imaging of therapy-induced anti-cancer immune responses in humans.

Authors:  Erik H J G Aarntzen; Mangala Srinivas; Caius G Radu; Cornelis J A Punt; Otto C Boerman; Carl G Figdor; Wim J G Oyen; I Jolanda M de Vries
Journal:  Cell Mol Life Sci       Date:  2012-10-05       Impact factor: 9.261

10.  Immunization route dictates cross-priming efficiency and impacts the optimal timing of adjuvant delivery.

Authors:  Isabelle Bouvier; Hélène Jusforgues-Saklani; Annick Lim; Fabrice Lemaître; Brigitte Lemercier; Charlotte Auriau; Marie-Anne Nicola; Sandrine Leroy; Helen K Law; Antonio Bandeira; James J Moon; Philippe Bousso; Matthew L Albert
Journal:  Front Immunol       Date:  2011-12-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.